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Accepted 24 March 2010AbstractObjective: To assess retrospectively the efficacy and safety of MONARC (American Medical Systems) transobturator suburethral slings in the
treatment of female urodynamic stress incontinence with and without low maximal urethral closure pressure (MUCP).
Materials and Methods: Seventy-three women with urodynamic stress incontinence, fitted with the transobturator suburethral sling at a medical
center in central Taiwan, participated in the study. Objective postoperative evaluations, including a 1-hour pad test, cough stress test, uro-
flowmetry, and residual urine volume, were conducted 6 months after operation. Subjective outcomes were evaluated by telephone interview.
Charts were reviewed for perioperative complications, urinary retention, and requirements for postoperative medication for symptoms of
urgency. The mean follow-up was 48 months.
Results: Objective cure rate was 80.8% (dry pad test and negative stress test), 82.4% for MUCP less than 30 cmH2O, and 80.4% for MUCP
greater than 30 cmH2O ( p¼ 1.000). Mean pad weight gain changed from 25.8 g preoperatively to 1.8 g postoperatively ( p< 0.05). There was
no significant change in urinary flow rate or residual volume. Subjectively, 98.6% of subjects experienced complete improvement; only one
patient found no improvement. Very few perioperative complications occurred. Immediate postoperative difficulty in voiding occurred in 6.8%
of patients. Postoperative de novo urgency was 2.7%.
Conclusions: The MONARC transobturator suburethral sling is a safe and highly effective treatment for stress urinary incontinence even in
women with low MUCP at a mean follow-up of 48 months. Evaluation of the outcomes after a longer follow-up period is necessary.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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The surgical treatment of urodynamic stress incontinence
(USI) because of urethral hypermobility has changed radically
since the introduction of the tension-free vaginal tape (TVT)
procedure first described by Ulmsten and Petros [1] in 1995.
Although TVT is effective, with success rates ranging from
84% to 95% [2e5], the retropubic placement of suburethral
slings has been associated with a variety of intra- and* Corresponding author. Division of Urogynecology and Reconstructive
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doi:10.1016/j.tjog.2011.01.027postoperative complications, including major blood vessel
injuries and perforations of the bladder, bowel and urethra [5].
In addition, postoperative voiding difficulties are fairly
common, with transient urine retention rates of between 8% and
17% [6e8]. Urgency also developed in 5e15% of subjects
[7e10]. These complications appear to be related to the passage
of metallic sling trocars through the retropubic space. In 2001,
a new surgical approach was described by Delorme [11], where
the needle passers run the sling through the obturator foramen.
The retropubic space is avoided, and a V-shaped hammock of
support is created for the urethra, rather than the U-shaped
urethral suspension of TVT. Ninety percent of Delorme’s
patients were cured, without perioperative complications and
postoperative voiding difficulties. To date, very few articlescs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Patients’ characteristics (n¼ 73)
Patients’ characteristics Value
Age (yr) 54.3  11.6
Parity 3.5  1.2
Body mass index 25.4  3.7
Intrinsic sphincter deficiency (MUCP< 30 cm H2O) 17 (23.3)
Hormone replacement therapy 3 (4.1)
Menopausal status 38 (52.1)
Prior hysterectomy 11 (15.1)
Previous surgery for prolapse 6 (8.2)
Data are presented as n (%) or mean  standard deviation.
MUCP¼maximal urethral closure pressure.
21M.-J. Sun, H.-D. Tsai / Taiwanese Journal of Obstetrics & Gynecology 50 (2011) 20e24have reported the outcome of transobturator suburethral sling
for intrinsic sphincter deficiency. Patients with intrinsic
sphincter deficiency are often more difficult to cure by surgery;
the cure rates of 74% obtained using the TVT procedure appear
to be equivalent to those achieved through traditional inconti-
nence operations [11]. The aim of this study is to evaluate and
report on the safety and efficacy of the transobturator sub-
urethral approach using the MONARC transobturator sub-
urethral sling for the treatment of USI; additionally, because the
grades of intrinsic urethral sphincter deficiency were deter-
mined by maximal urethral closure pressure (MUCP) values in
our hospital, we would like to know if patients with low MUCP
(<30 cm H2O) would suffer a worse outcome.
Materials and methods
From March 2004 to August 2005, 80 consecutive patients
with USI underwent the transobturator suburethral sling
technique (MONARC, American Medical Systems). All of the
women who were confirmed with USI were candidates for
inclusion. Patients with predominant urge incontinence, uro-
dynamic detrusor overeactivity, previous failed incontinence
surgery, or loss of follow-up were excluded. All patients
included had been indicated for surgical treatment of their USI
with or without a concomitant reconstructive procedure.
Patients with MUCP less than 20 cm H2O were diagnosed
with intrinsic urethral sphincter deficiency or USI Type III
according to International Continence Society. However, very
few patients had MUCP less than 20 cmH2O, so we adopted
the method of de Tayrac et al [12], who also grouped patients
with a cut off value of MUCP less than 30 cmH2O for special
occasions. Although this grouping does not follow the Inter-
national Continence Society standard, the observations of the
grouped patients remain valuable.
The preoperative evaluation included a medical history,
urogynecologic examination (pelvic examination and genital
prolapse examination), Q-tip test, cough provocation stress test,
1-hour pad test, a voiding diary kept for at least 2 weeks, and
urodynamics. An assessment of postoperative efficacy and
safety was conducted at 1, 6, and 12 months. Postoperative
uroflowmetry, residual urine, urine sediment analysis, the 1-
hour pad test, and cough provocation stress test were performed
6 months postoperatively. Subjective cure evaluations were all
performed in August 2008 simultaneously (the mean post-
operative time for the telephone interview was 48 months,
ranging from 42.1 months to 60.6 months) by telephone inter-
view and a cure was defined as the absence of any subjective
complaint of urine leakage; patients were considered to have
improvedwhen the number of their stress incontinence episodes
were said to have been reduced by half. Patients who still had
a subjective complaint of leakage were considered failures. We
defined “objectively cured” as a patient who had a negative
stress test and dry pad test. Postoperative voiding difficulty was
defined as residual urine of more than 100 mL, any experience
of hesitancy in voiding, weak stream or a discontinuous flow, or
an amount of postvoid residual more than two-thirds of that
from self-voiding. All of the patients were also asked to assesstheir own postoperative voiding function through the use of
a voiding diary.
Patients were also asked to rate their overall satisfaction
with the surgical outcome as being: very satisfied, moderately
satisfied, not very satisfied, or not at all satisfied.
All of the patients were operated on according to the
MONARC technique described by Dargent et al [10]. All of the
procedures were carried out under general anesthesia in
the lithotomy position. A Foley catheter was inserted to empty
the bladder completely, and a 2-cm incision was made along the
anterior vaginal mucosa and 0.5 cm below the urethral meatus.
For the concomitant reconstructive procedure, the MONARC
procedure was performed after the vaginal hysterectomy and
anterior vaginal repair. Cystoscopy was performed in the initial
10 cases but was thereafter abandoned because there were never
any signs of bladder injury during follow-up. Forceps were
placed between the mesh and the urethra to adjust the mesh
tension, leaving a gap of approximately 3e5 mm between the
urethra and the mesh. The excess tape was cut off at the skin
incision. The vaginal incision was closed with interrupted
sutures of gradually absorbable thread.
A urinary catheter was inserted before the MONARC
implant and removed on the day following surgery. The
postvoid residual was then measured before the patient was
discharged from the hospital. In cases of voiding difficultly
(i.e. >100 mL residual urine), hospitalization was prolonged
until a postvoid residual less than 100 mL was obtained.
Statistical analysis was based on the student t test for para-
metric, and the Wilcoxon signed Ranks test or McNemar test
for nonparametric continuous variable categorical variables. A
p value less than 0.05 were considered to denote a significant
difference.Results
Seventy-three patients were included in this study and 7 were
excluded because of loss of follow-up data. The basic back-
ground of the study subjects is shown in Table 1. Fourteen
patients (19.2%) underwent theMONARC sling operation alone,
whereas 51 (69.9%) underwent at least one concomitant recon-
structive procedure at the time of implant. The mean operative
time taken to implant the MONARC sling for the patients who
underwent the MONARC alone was 15.2 5.0 minutes. There
Table 2
Operative and postoperative complications of MONARC (n¼ 73)
Complication n (%)
Bladder perforation 0 (0)
Hemorrhage or hematoma 0 (0)
Postoperative urinary retention (RU> 100 cc) 5 (6.8)
Voiding difficulty on postoperative visit (3e6 mo) 14 (19.2)
Voiding difficulty on telephone interview (13 mo) 1 (1.4)
Fever (>38C) 0 (0)
Urinary tract infection 17 (23.3)
De novo urgency/frequency 2 (2.7)
De novo urgency/frequency at postoperative visit 6 (8.2)
De novo urgency/frequency at telephone interview 1 (1.4)
Vaginal or urethral erosion 0 (0)
RU¼ residual urine.
Table 4
Preoperative and postoperative urodynamic parameter
Urodynamic parameters Preoperative Postoperative pa
Q maximum (mL/s) 19.1 9.3 19.7 8.7 0.576
Q average (mL/s) 10.1 5.2 11.5 13.9 0.829
Residual urine (mL) 32.5 75.5 40.3 85.1 0.806
a By Wilcoxon signed Ranks test.
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postoperative voiding difficulty was reported in five (6.8%)
patients and all recovered a normal voiding function (residue
urine less than 100 mL) within a week after prolonged
indwelling catheter and drug medication; although the post-
operative subjective response at 6months showed 19.2% voiding
difficulty. Postoperative evaluations at 6 months (Table 3)
showed a cure rate of 80.8% (patients dry on both the 1-hour pad
test and cough stress test). The cure rate among patients with
a lower MUCP (<30 cm H2O) was 82.4% (14/17). Among all
patients, the mean pad weight gain changed from 25.9 g preop-
eratively to 1.7 g postoperatively ( p< 0.05); for the low MUCP
patients, the change was from 39.0 to 0.9 g ( p¼ 0.05). The
uroflowmetry and residual urine showed no significant change at
the 6 months follow-up visit. As of the last follow-up visit, there
were no urethral, bladder, bowel, or neurovascular injuries and
no vaginal or urethral erosions. Postoperative de novo urgency
was reported by two (2.7%) patients.
Subjective outcome and satisfaction were evaluated during
the most recent postoperative telephone interviews, with an
average follow-up of 48 months. Seventy-two of 73 patients
(98.6%) were cured, no patient (0%) improved, and one
patient (1.4%) failed. Most patients were satisfied: 59 of 73
(80.8%) were very satisfied, 9 of 73 (2.3%) were moderately
satisfied, 4 of 73 (5.5%) were not very satisfied, and 1 of 73
(1.4%) was dissatisfied.
The preoperative and postoperative uroflowmetry evalua-
tion for the MONARC did not reveal a statistically significant
difference (Table 4).Table 3
Objective surgical outcome of MONARC based on stress test and 1-hour pad test
Surgical outcome MUCP< 30 cmH2O
(n¼ 17)
Cure rate, n(%) 14 (82.4)
Curednegative stress test and dry pad test
Pad test
Preoperative (g) 39.0 35.0
Postoperative (g) 0.9 3.2
Change (g) 38.0 33.3
MUCP¼maximal urethral closure pressure.Discussion
TVT procedure is the first of a new generation of minimally
invasive operations for the treatment of female USI [13].
Systemic prospective clinical trials have proved that the TVT
procedure is effective and safe in curing stress incontinence [14].
Through assessment by strict objective and subjective outcome
measures, cure rates of 85% have been reported, with another
5e10% showing significant improvement [13], and preliminary
analysis of the 7-year results of Nilsson [14] indicates a cure rate
of 81%. Because TVT is a simple minimally invasive procedure
that can be performed under local anesthesiawith high cure rates,
it is themost preferred surgical treatment for femaleUSI in some
countries [15]. However, because theTVT trocar is directed from
the vagina to the retropubic area in an essentially blindmanner, it
can cause bladder injuries and rare but life-threatening injuries to
the bowels or large vessels [15,16]. Because most of these
complications seem to be related to the penetration of the ret-
ropubic space, a new surgical procedure that retains the same
midurethra position as that of TVT while maintaining or even
improving efficacy by reducing or eliminating the complications
related to the penetration of the retropubic space has been
invented. The original description of this new technique was
published by Delorme [11] in 2001, whereby he placed the tape
between the two obturator foramen, creating a hammock-like
support for the urethra instead of urethral suspension, as with
TVT [17]. Delorme [11,18] has reported in two articles that
MONARC is a safe and effective surgical procedure for the
treatment of female USI, with an 83% cure rate and a 5.4%
improvement at 6 months follow-up. Two recent comparative
studies of MONARC versus TVT [12,19] reported no difference
in terms of efficacy. MONARC represents an easily performed
and reproducible procedure. A study by Costa et al [17]
confirmed the hypothesis that MONARC may dramatically
reduce intraoperative complications by avoiding the retropubic
space, indicating an overall complication rate of 2.2% (bladder
perforation, urethral perforations, and number of vaginal lateralat 6-month postoperation
MUCP> 30 cmH2O
(n¼ 56)
Total
(n¼ 73)
p
45 (80.4) 59 (80.8) 1.000
22.1 38.5 25.9 38.2 0.043
2.0 6.2 1.7 5.7
20.1 38.0 24.1 37.5
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which can be up to 15% [20]. After incorporating the use of the
index finger into the vaginal incision to protect the urethra, no
urethral injury has been reported [17]. In this study, therewere no
intraoperative complications and no urethral, bladder, bowel, or
vascular injuries. Voiding difficulties with retention problems
and de novo urge symptoms are the other complications that are
most frequently associated with anti-incontinence operations,
whereas the traditional incontinence operation had an incidence
rate of more than 30% [13]. TVT has shown postoperative
voiding difficulties of transient urine retention in 8e17% [6e8]
and urgency in 5e15% [7e9] of patients. Delorme [11] reported
no postoperative voiding difficulties in his research into using the
transobturator approach. de Tayrac et al [12] prospectively
compared TVTandMONARC for the surgical treatment of USI
in women. The rate of postoperative urinary retention was 25%
in the TVT group versus 13.3% in the MONARC group
(p> 0.05) [12]. In this study, 6.8% of patients experienced
transient voiding difficulties. It has been hypothesized that, with
the retropubic approach, the U-shaped sling kinks the urethra,
whereaswith the obturator approach, the sling is positionedmore
horizontally, reestablishingmore natural lateral support [15] and
so decreasing the risk of postoperative voiding difficulties.
Although serious complications appear to be reduced and early
studies have shown promise, the long-term efficacy of the
transobturator suburethral approach has not yet been established
and thus requires long-term observation. There was no signifi-
cant difference in the incidence of postoperative de novo urgency
between the use of the MONARC (6.7%) and TVT (6.5%) [12],
whereas in the study by Deval et al [21], SPARC showed a de
novo urgency symptom incidence of 11.5%. In our study of
MONARC, therewas only a 2.7% incidence of de novo urgency.
This lower incidence of postoperative de novo urgency may be
because of the less-invasive surgical procedure and less tension
around the urethra.
Hemorrhagic complications can occur intraoperatively
during needle insertion. Therewas about a 2e4% rate in the five
studies of TVT [22]. The transobturator suburethral approach
has been introduced to minimize the risk of complications
arising from the retropubic passage of the needle. No significant
bleeding or hematoma complication has been reported [23]. In
this study, there were no symptomatic hemorrhagic complica-
tions, although we did not perform routine postoperative
ultrasound scans.
Patients with intrinsic sphincter deficiency are often more
difficult to cure by surgery; the cure rates of 74% obtained
through the TVT procedure seem to be equivalent to those
achieved by traditional incontinence operations [11]. Delorme
et al [18] reported a 100% cure rate for preoperative maximum
urethral closure pressure less than 20 cmH2O. Guerette et al [24]
reported that a transobturator slings should be used with caution
in women with impaired urethral function (Valsalva leak-point
pressure less than 60 cmH2O and MUCP less than 40 cmH2O)
[24]. In our study, there were 17 cases of low MUCP
(<30 cmH2O), with an 82.4% objective cure rate. We recognize
that this outcome would vary with different surgeons, and that
the results for patients with low MUCP appear to differ from thepast researches related toMONARC. This may be because of the
small sample size, and patients with low MUCP will need
a longer follow-up period and more powerful evaluation in the
future.
In conclusion, this is a rare study of the use ofMONARC and
USI in Asia, which may provide a useful reference. The
MONARC transobturator suburethral sling results in a high
continence rate and has the advantage of avoiding many of the
risks normally associated with the retropubic approach, poten-
tially reducing the incidence of serious potential complications.
The medium-term results presented here show that the trans-
obturator suburethral sling is a safe, simple, and effective
treatment for women with USI, even for those with low MUCP.
An evaluation of the outcome after a longer follow-up period is
required to validate this procedure for the long term.References
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